Precision oncology has focused on mutations. Spatial profiling adds the microenvironmental context that increasingly explains why matched therapies still fail.
Spatial biology and digital pathology are converging on the same tissue slide. Their merger is what will actually bring spatial insights to clinical decisions.
Pathology has always been spatial. Now it is becoming molecular and computational too, and the fusion of the two is a genuinely new diagnostic substrate.
Spatial assays are complex, multi-step, and image-dependent, exactly the profile regulators scrutinize hardest. Knowing the path early shapes development
A spatial biomarker is not just what is present in a tissue. It is what is present, where, and next to what. That extra dimension is where the predictive power lives.
Immuno-oncology’s next generation of targets and biomarkers is emerging from spatial data, where the interactions checkpoint drugs act on are finally visible.
The next generation of biomarkers will not be single molecules but spatial patterns. Getting from a promising pattern to an approved diagnostic is its own discipline.
From automated experiments to AI-powered analysis, connected data, and smarter resource use, digital technologies are reshaping how scientists work — and what the laboratory itself can do.
From automated experiments to AI-powered analysis, connected data, and smarter resource use, digital technologies are reshaping how scientists work — and what the laboratory itself can do.